Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fasudil - Asahi Kasei/Woolsey Pharmaceuticals

Next Previous
Drug Profile

Fasudil - Asahi Kasei/Woolsey Pharmaceuticals

Alternative Names: AT 877; BRAVYL® ; Chuanwei; Eril; Eril Injection; HA 1077; WP-0512

Latest Information Update: 18 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asahi Kasei
  • Developer Asahi Kasei; Asahi Kasei Pharma Corp; Eisai Co Ltd; Tianjin Chase Sun Pharmaceutical; Woolsey Pharmaceuticals
  • Class Amines; Anti-ischaemics; Ischaemic heart disorder therapies; Isoquinolines; Small molecules; Sulfonamides
  • Mechanism of Action Calcium channel antagonists; Protein kinase C inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corticobasal degeneration; Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebral ischaemia; Cerebral vasospasm
  • Phase II Amyotrophic lateral sclerosis; Corticobasal degeneration; Dementia; Progressive supranuclear palsy
  • No development reported Pulmonary arterial hypertension
  • Discontinued Angina pectoris; Atherosclerosis; HIV-1 infections; Intracranial thrombosis

Most Recent Events

  • 11 Feb 2022 Woolsey Pharmaceuticals completed the phase IIa FOUND trial in Dementia (In adults, In the elderly) in USA and Australia (PO) (NCT04793659)
  • 22 Dec 2021 Phase-II clinical trials in Amyotrophic lateral sclerosis (In adults, In the elderly) in USA (PO) (NCT05218668)
  • 18 Feb 2021 Fasudil - Asahi Kasei/Woolsey Pharmaceuticals receives Orphan Drug status for Corticobasal degeneration in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top